EN ▾

ConfirmedMedicine30 Oct, 11:00 UTC

Biotech investor Bruce Booth predicts AI drug design will worsen pharma R&D productivity for three to five years

In a LifeSciVC essay he argues AI mainly democratises molecular design around known targets, scaffolds and biology, creating 'drug abundance' and crowding rather than cracking novel biology; it is an opinion piece, not a study.

Read at LifeSciVC (Bruce Booth)

More from Snape Report

Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model
Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
Apple says Apple Intelligence features will reach China with iOS 27.3, using Alibaba's Qwen in Siri and Writing Tools
Anthropic renames Claude Max 20x to Ultra and drops the 5-hour limit for verified Ultra accounts
Google, Microsoft, OpenAI and Anthropic back a shared robots.txt signal for opting out of AI training